Multiple Sclerosis In The Crossfire 2009: New Therapies for MS
New Therapies for MS
With a plethora of new therapies on the horizon, there are significant issues to be addressed for those who manage MS. This year's program, again divided into two parts for easier viewing, is designed to provide both data and insights about these new therapies and how they may contribute to the changing face of MS management.
In Part 1, Dr. Omar Khan and his panel of distinguished MS experts will discuss
the current treatment landscape and the benefit/risk profiles of 2 new oral immunosuppressant agents, cladribine and fingolimide.
Part 2 will provide an overview of oral immunomodulators such as laquinimod
and teriflumamide as well as consideration of the next generation of monoclonal antibody infusions.
MS In The Crossfire 2009
Recorded live on September 29, 2009, at the Studios of Detroit Public Television, Detroit, MI
Each part of the 2009 program is eligible for 1 AMA PRA Category 1 Credit™, for a total of 2.0 credits.
Sponsored and Supported by:
This continuing medical education activity is jointly sponsored by Ciné-Med Inc. and Astute Technology.
This activity is supported by an educational grant from Teva Neuroscience.
2009 Distinguished Faculty
Omar Khan, MD, FRCP
Moderator
Timothy Vollmer, MD
Panelist
Bruce Cree, MD, PhD, MCR
Panelist
Gary Birnbaum, MD
Panelist
In the Crossfire 2008: The Emerging Face of MS
Two informative programs provide discussions of some of the latest findings about the immunopathology of MS, new imaging study data and updated information about the clinical effects of disease-modifying therapy.